Stockscreener 앱 받기
3.74
0.53%
-0.02
시간 외 거래:
3.75
0.010
+0.27%
Voyager Therapeutics Inc 주식(VYGR)의 최신 뉴스
HC Wainwright Analysts Increase Earnings Estimates for VYGR - MarketBeat
Voyager Therapeutics at Stifel 2026 CNS Forum: Year of Tau Focus - Investing.com Canada
H.C. Wainwright reiterates Voyager Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Analysts Set Expectations for VYGR Q1 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Voyager Therapeutics (VYGR) and Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Voyager Therapeutics (VYGR): Analyst Reiterates Buy Rating and M - GuruFocus
Voyager Therapeutics' (VYGR) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Truist reiterates Buy on Voyager Therapeutics stock ahead of data By Investing.com - Investing.com Canada
Truist reiterates Buy on Voyager Therapeutics stock ahead of data - Investing.com
Voyager Therapeutics Stock (ISIN: US92916U1025) Eyes Major Upside Amid Gene Therapy Pipeline Momentu - AD HOC NEWS
Voyager Therapeutics (NASDAQ:VYGR) Upgraded to Hold at Wall Street Zen - MarketBeat
Insider Trends: Can Voyager Therapeutics Inc reach all time highs this year - baoquankhu1.vn
Is Voyager Therapeutics (VYGR) Balancing Pipeline Ambition With Sustainable Losses After Its 2025 Results? - Sahm
Does Voyager Therapeutics’ (VYGR) Widening Annual Loss Redefine the Risk-Reward in Its Neurology Pipeline? - Yahoo Finance
Guggenheim Remains a Buy on Voyager Therapeutics (VYGR) - The Globe and Mail
Wells Fargo Sticks to Their Buy Rating for Voyager Therapeutics (VYGR) - The Globe and Mail
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Voyager Therapeutics Faces Rising Tariff and U.S.–China Geopolitical Risks as BIOSECURE Act Threatens Key Chinese CDMO Partnerships - The Globe and Mail
Voyager Therapeutics (VYGR) Gets a Buy from H.C. Wainwright - The Globe and Mail
Voyager Therapeutics (VYGR) Q4 Loss Of US$27 Million Reinforces Bearish Profitability Concerns - Sahm
Voyager Therapeutics, Inc. 2025 Annual Report: Key Risks, Forward-Looking Statements, and Business Overview - Minichart
Voyager Therapeutics Inc earnings beat by $0.05, revenue topped estimates - Investing.com Australia
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and West Pharmaceutical Services (WST) - The Globe and Mail
Voyager Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Voyager Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Voyager Therapeutics Q4 2025 Financial Report: Revenue Surpasses EstimatesNews and Statistics - IndexBox
Voyager (VYGR) Surpasses Q4 Revenue Expectations, Sets Strategic Vision for 2026 - GuruFocus
Voyager Therapeutics: Fourth Quarter Earnings Overview - Bitget
Gene therapy pioneer Voyager Therapeutics Inc (stock code: VYGR) announced that by the end of fiscal year 2025, the company held strong cash and cash equivalents totaling $202 million. - Bitget
Voyager Therapeutics (NASDAQ:VYGR) Announces Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat
Voyager Therapeutics: Q4 Earnings Snapshot - KING5.com
Voyager Therapeutics reports Q4 2025: $15.3M Q4 collaboration revenue, $119.7M full-year net loss - TradingView
Voyager Therapeutics Q4 net loss narrows - TradingView
Voyager Therapeutics 2025 10-K: Collaboration revenue $40.4M, Net loss $(119.7)M - TradingView
Voyager (Nasdaq: VYGR) 2025 loss but cash runway into 2028 - Stock Titan
Earnings Breakdown: Voyager Therapeutics Q4 - Benzinga
BRIEF-Voyager Therapeutics Q4 EPS USD -0.46 - TradingView
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results - GlobeNewswire
Is Voyager Therapeutics Inc. stock trading at a premium valuation2026 Summary & Expert-Curated Trade Recommendations - Naître et grandir
Will Voyager Therapeutics Inc. stock gain from lower inflationEarnings Growth Report & Fast Entry Momentum Alerts - mfd.ru
Voyager Therapeutics Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Voyager Therapeutics (VYGR) to Release Quarterly Earnings on Tuesday - MarketBeat
Voyager Therapeutics Touts Tau, Gene Therapy and NeuroShuttle Roadmap, Sees Cash Runway Into 2028 - Defense World
Voyager Therapeutics at Oppenheimer Conference: Strategic Insights on Alzheimer’s By Investing.com - Investing.com Canada
Todd Alfred Carter Sells 4,174 Shares of Voyager Therapeutics (NASDAQ:VYGR) Stock - MarketBeat
Voyager Therapeutics (NASDAQ:VYGR) CFO Sells $17,598.36 in Stock - MarketBeat
Voyager Therapeutics (NASDAQ:VYGR) CEO Alfred Sandrock Sells 14,197 Shares - MarketBeat
Robin Swartz, Voyager Therapeutics COO, sells $24k in VYGR stock - Investing.com Canada
Alfred Sandrock, Voyager Therapeutics CEO, sells $53806 in stock By Investing.com - Investing.com Canada
Voyager Therapeutics CFO sells $17,598 in stock By Investing.com - Investing.com Canada
VYGR | Voyager Therapeutics, Inc. Common FinancialsIncome Statement - Quiver Quantitative
Voyager Therapeutics (VYGR) CFO executes 4,668-share tax sell-to-cover trade - Stock Titan
Voyager Therapeutics (VYGR) CSO auto-sells shares for tax bill - Stock Titan
Voyager Therapeutics (NASDAQ:VYGR) COO Robin Swartz Sells 6,458 Shares - MarketBeat
Earnings Miss: How does Voyager Therapeutics Inc compare to its peersGlobal Markets & Accurate Buy Signal Notifications - baoquankhu1.vn
ARMISTICE CAPITAL, LLC Reduces Stake in Voyager Therapeutics Inc. - GuruFocus
4,174-Share Rule 144 Notice for Voyager Therapeutics (NASDAQ: VYGR) - Stock Titan
VYGR (NASDAQ: VYGR) Rule 144 notice: 6,458 shares tied to vesting - Stock Titan
1.20%
0.06%
자본화:
|
볼륨(24시간):